Compare FBGL & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBGL | CELZ |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.1M |
| IPO Year | 2022 | 2008 |
| Metric | FBGL | CELZ |
|---|---|---|
| Price | $0.44 | $1.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 183.5K | ★ 11.6M |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.34 | $0.62 |
| 52 Week High | $1.40 | $6.25 |
| Indicator | FBGL | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 56.82 |
| Support Level | $0.37 | $0.74 |
| Resistance Level | $0.65 | $2.42 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 29.52 | 47.60 |
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply, and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture, as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and sales of construction materials.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.